<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03520985</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 39/16 - OptiPOM</org_study_id>
    <nct_id>NCT03520985</nct_id>
  </id_info>
  <brief_title>Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma</brief_title>
  <acronym>OptiPOM</acronym>
  <official_title>Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma. A Multi-center, Single Arm Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pomalidomide is an approved treatment for refractory multiple myeloma. Toxicity of
      pomalidomide in the pivotal MM-003 trial, was considerable, with 60% of patients experiencing
      drug-related G3/4 toxicity. Neutropenia (48% vs 16%) and pneumonia (13% vs 8%) were
      significantly more common in the pomalidomide arm. This resulted in frequent dose
      interruptions (67%) and dose reductions (27%). This suggests that for the majority of
      patients the 4 mg daily dosing schedule is too toxic, and that strategies to deliver reduced
      dosing of pomalidomide are of high practical relevance. The aim of this trial therefore is to
      establish that alternate day dosing of pomalidomide (4 mg q2d, d1-28) is non-inferior to
      daily dosing (4 mg d1-21 q28) in terms of efficacy of the drug with potentially less side
      effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple myeloma (MM) accounts for 1% of all cancers and ∼10% of all hematological
      malignancies. Despite recent advances in myeloma treatment, including the introduction of
      proteasome inhibitors, immunomodulatory drugs (IMiDs) and stem cell transplantation, myeloma
      remains an incurable disease. The treatment of bortezomib and lenalidomide refractory myeloma
      is still an unmet medical need. Once patients have relapsed after IMiD-containing therapies
      and have become bortezomib-resistant, their prognosis is extremely poor.

      Pomalidomide is a third-generation, Swissmedic approved, oral immunomodulatory drug with
      activity in such patients. Toxicity of pomalidomide in the pivotal MM-003 trial, however, was
      considerable, with 60% of patients experiencing drug-related G3/4 toxicity. Neutropenia (48%
      vs 16%) and pneumonia (13% vs 8%) were significantly more common in the pomalidomide arm.
      This resulted in frequent dose interruptions (67%) and dose reductions (27%). This suggests
      that for the majority of patients the 4 mg daily dosing schedule (4 mg daily on 21 of 28
      days) is toxic, and that strategies to deliver reduced dosing of pomalidomide are of high
      practical relevance.

      Alternative dosing schedules There are robust data available that lower pomalidomide doses
      (e.g. 2 mg daily) lead to similar responses and progression free survival with fewer side
      effects. Due to its unique pharmacological characteristics, pomalidomide is well suited for
      alternate day dosing. The decline of the plasma concentration at the terminal phase is slow.
      These data make pomalidomide an ideal candidate for alternate day dosing. Therefore, a Phase
      1 study has already been conducted in 2008 to test the alternating administration of the drug
      showing excellent responses with a marked reduction of thrombotic events and less severe
      myelosuppression.

      The drug costs of pomalidomide are high (Switzerland: 12.400 CHF per 4 week cycle; US: 13.700
      US$ per 4 week cycle). Interestingly, the manufacturer chose a pricing model that is
      independent from the capsule strength (costs for one capsule 1 mg=2 mg=3 mg=4 mg). In
      patients requiring dose reductions due to hematologic toxicity, daily dosing of reduced
      strength pomalidomide (e.g. 2 mg daily) is approved and suggested by the manufacturer. This
      delivers 50% less pomalidomide to the patient, albeit at 100% of the price of full dosing.

      In summary, the establishment of the modified pomalidomide schedule would be an interesting
      option for our patients to achieve similar efficacy with fewer side effects. In addition
      optimizing the cost-effectiveness of the drug.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2018</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>From date of registration until 28 days after last dose of trial medication with longest treatment time of approximately 36 months</time_frame>
    <description>OR is defined as minimal response or better, assessed according to the IMWG criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From date of registration until 28 days after last dose of trial medication with longest treatment time of approximately 36 months</time_frame>
    <description>OS is defined as the time from registration until death from any cause. Patients not having an event at the time of analysis will be censored at the date they were last known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) at 12 months</measure>
    <time_frame>at 12 months</time_frame>
    <description>OS, as defined above, will be evaluated at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From date of registration until 28 days after last dose of trial medication with longest treatment time of approximately 36 months</time_frame>
    <description>PFS is defined as the time from registration until progression according the IMWG criteria or death from any cause, whichever occurs first. Patients not having an event at the time of analysis as well as patients starting a new anticancer therapy in the absence of an event will be censored at the date of their last tumor assessment showing non-progression before starting a new treatment, if any.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Pomalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment in this trial consists of oral pomalidomide on alternate days (ad) plus Low-Dose Dexamethasone (adPOM + LD-DEX)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Pomalidomide (4 mg p.o.) will be administered on every other day of each 28-day treatment cycle.
Treatment duration:
Treatment cycles are repeated until disease progression.</description>
    <arm_group_label>Pomalidomide</arm_group_label>
    <other_name>Imnovid®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>For patients ≤ 75 years of age:
Low-Dose Dexamethasone (40 mg p.o.) will be administered once per day on Days 1, 7, 15, and 21 of a 28-day cycle.
For patients &gt; 75 years of age:
Low-Dose Dexamethasone (20 mg p.o.) will be administered once per day on Days 1, 7, 15, and 21 of a 28-day cycle.
Treatment duration:
Treatment cycles are repeated until disease progression.</description>
    <arm_group_label>Pomalidomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion criteria:

          -  Patient was diagnosed with multiple myeloma based on standard IMWG criteria

          -  Prior treatment with ≥ 2 treatment lines of anti-myeloma therapy

          -  Patients must have failed both lenalidomide and bortezomib

          -  Measurable disease for myeloma defined as one of the following: serum M-protein ≥ 5
             g/L; urine M-protein ≥ 0.2 g/24 hours

          -  Refractory or relapsed and refractory disease defined as documented disease
             progression during or within 60 days of completing their last myeloma therapy.

          -  Adequate hematological, hepatic and renal function

          -  A negative pregnancy test before inclusion into the trial is required for all women
             with child-bearing potential

        Key exclusion criteria:

          -  History of hematologic or primary solid tumor malignancy, unless in remission for at
             least 3 years from registration, with the exception of pT1-2 prostate cancer Gleason
             score &lt;6, adequately treated, cervical carcinoma in situ or localized non-melanoma
             skin cancer.

          -  Polyneuropathy grade &gt; 2

          -  Patients who received any of the following within the last 14 days of initiation of
             trial treatment:

          -  Plasmapheresis

          -  Major surgery (kyphoplasty is not considered major surgery)

          -  Radiation therapy

          -  Use of any anti-myeloma drug therapy

          -  Known or clinically suspected Myeloma manifestations in the central nervous system

          -  Severe or uncontrolled cardiovascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thilo Zander, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Luzerner Kantonsspital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christoph Driessen, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christoph Renner, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Onkozentrum Zürich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Fuhrer, PhD</last_name>
    <phone>+41 31 389 91 91</phone>
    <email>trials@sakk.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kantonspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Heizmann, MD</last_name>
      <phone>+41 62 838 60 50</phone>
      <email>marc.heizmann@ksa.ch</email>
    </contact>
    <investigator>
      <last_name>Marc Heizmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sabine Gerull, MD</last_name>
      <phone>+41 61 265 25 25</phone>
      <email>sabine.gerull@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Sabine Gerull, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Svizzera Italiana IOSI</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erika Lerch, MD</last_name>
      <phone>+41 91 811 91 11</phone>
      <email>erika.lerch@eoc.ch</email>
    </contact>
    <investigator>
      <last_name>Erika Lerch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Pabst, Prof.</last_name>
      <phone>+41 31 632 84 30</phone>
      <email>thomas.pabst@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Thomas Pabst, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulrich Mey, MD</last_name>
      <phone>41-81-256-7170</phone>
      <email>ulrich.mey@ksgr.ch</email>
    </contact>
    <investigator>
      <last_name>Ulrich Mey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Fribourgeois HFR</name>
      <address>
        <city>Fribourg</city>
        <zip>1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Betticher, Prof</last_name>
      <phone>+41(0)26 426 72 40</phone>
      <email>daniel.betticher@h-fr.ch</email>
    </contact>
    <investigator>
      <last_name>Daniel Betticher, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Cairoli, MD</last_name>
      <phone>41-21-314-4182</phone>
      <email>anne.cairoli@chuv.ch</email>
    </contact>
    <contact_backup>
      <last_name>Cairoli</last_name>
    </contact_backup>
    <investigator>
      <last_name>Anne Cairoli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Liestal</name>
      <address>
        <city>Liestal</city>
        <zip>CH-4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Geneviève Favre, MD</last_name>
      <phone>+41 61 925 27 11</phone>
      <email>genevieve.favre@ksbl.ch</email>
    </contact>
    <investigator>
      <last_name>Geneviève Favre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Luzerne</city>
        <zip>CH-6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thilo Zander, MD</last_name>
      <phone>+41 41 205 11 11</phone>
      <email>thilo.zander@luks.ch</email>
    </contact>
    <investigator>
      <last_name>Thilo Zander, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tobias Silzle, MD</last_name>
      <phone>+41 71 494 11 11</phone>
      <email>tobias.silzle@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Tobias Silzle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regionalspital Thun</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Rauch, MD</last_name>
      <phone>+41 33 226 22 27</phone>
      <email>daniel.rauch@spitalstsag.ch</email>
    </contact>
    <investigator>
      <last_name>Daniel Rauch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Natalie Fischer, MD</last_name>
      <phone>+41 52 266 40 87</phone>
      <email>natalie.fischer@ksw.ch</email>
    </contact>
    <investigator>
      <last_name>Natalie Fischer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik Hirslanden</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Renner, Prof</last_name>
      <phone>+41 43 344 33 44</phone>
      <email>christoph.renner@hirslanden.ch</email>
    </contact>
    <investigator>
      <last_name>Christoph Hirslanden, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Markus G. Manz, Prof</last_name>
      <phone>+41 44 255 38 99</phone>
      <email>markus.manz@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Markus G. Manz, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2018</study_first_submitted>
  <study_first_submitted_qc>May 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2018</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory Multiple Myeloma</keyword>
  <keyword>Phase II</keyword>
  <keyword>Pomalidomide</keyword>
  <keyword>OptiPOM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

